CURE’s breast cancer page is an extensive resource of cancer information featuring the latest breast cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on breast cancer.
August 31st 2025
Women with HR+ early breast cancer who paused endocrine therapy to become pregnant breastfed without increased risk of recurrence in the short term.
Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer
June 11th 2015Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.
Adding Ibrance to Faslodex Delays Progression of Hormone Receptor-Positive Breast Cancer
June 1st 2015By adding the targeted drug Ibrance to the hormonal drug Faslodex, women with previously treated hormone receptor (HR)-positive, HER2-negative breast cancer delayed disease progression by more than five months.